Zovighian Bernard J 4
4 · Edwards Lifesciences Corp · Filed May 11, 2026
Research Summary
AI-generated summary of this filing
Edwards (EW) CEO Bernard Zovighian Receives Stock Awards
What Happened
Bernard J. Zovighian, CEO and Director of Edwards Lifesciences (EW), received new equity awards on May 7, 2026 under the company's Long‑Term Stock Incentive Program. The filing shows awards totaling 332,900 shares (includes time‑based and performance/derivative awards). To cover tax liabilities associated with these awards, 9,551 shares were surrendered (withheld) on May 7–8 for a total cash value of $792,268. Separately, gift/transfer transactions totaling about 9,711 shares occurred on May 8 and May 11. These transactions are award grants and transfers, not open‑market purchases or sales.
Key Details
- Primary award date: May 7, 2026 — new awards reported totaling 332,900 shares (includes derivative/performance awards).
- Tax withholding: 4,153 shares surrendered at $83.20 each = $345,530 (May 7); 5,398 shares surrendered at $82.76 each = $446,738 (May 8). Total withheld = 9,551 shares / $792,268.
- Gifts/transfers: 4,222 shares (May 8) and 5,489 shares (May 11) — total ~9,711 shares reported as gifts/transfers.
- Vesting and award types (per filing footnotes):
- Time‑based RSUs: granted May 7; vest in four equal annual installments starting one year after grant (Footnote F1).
- Stock options: granted May 7; vest monthly over ~36 months beginning one month after grant (Footnote F2).
- Performance RSUs (Target Award): granted May 7; target amount vests on May 7, 2029 subject to performance (0%–200%) (Footnote F3).
- Shares owned after these transactions: not disclosed in this Form 4 (filing notes it reflects changes only).
- Filing timeliness: Reported May 11, 2026 for May 7 transactions — filed within the required 2 business days.
Context
These entries primarily reflect equity compensation (awards and options) and routine tax withholding (code F) rather than an open‑market sale or purchase. Gift/transfer entries (code G) are transfers and do not necessarily indicate the insider’s view of the company’s stock. The performance RSUs are subject to future vesting and may pay out between 0%–200% of the target depending on results through 2029.
Insider Transaction Report
- Award
Common Stock
[F1]2026-05-07+43,800→ 124,057.65 total - Tax Payment
Common Stock
2026-05-07$83.20/sh−4,153$345,530→ 119,904.65 total - Gift
Common Stock
2026-05-08−4,222→ 115,682.65 total - Tax Payment
Common Stock
2026-05-08$82.76/sh−5,398$446,738→ 110,284.65 total - Gift
Common Stock
2026-05-11−5,489→ 104,795.65 total - Gift
Common Stock
2026-05-08+4,222→ 16,261.551 total(indirect: By Trust) - Gift
Common Stock
2026-05-11+5,489→ 21,750.551 total(indirect: By Trust) - Award
Employee Stock Option (Right to Acquire)
[F2]2026-05-07+245,300→ 245,300 totalExercise: $82.76From: 2027-05-07Exp: 2033-05-06→ Common Stock (245,300 underlying) - Award
Performance Rights
[F3]2026-05-07+43,800→ 43,800 totalFrom: 2029-05-07→ Common Stock (43,800 underlying)
- 3,733.56(indirect: By 401(k))
Common Stock
Footnotes (3)
- [F1]These restricted stock units were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.
- [F2]These options were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments.
- [F3]Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2029. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 200% of the Target Awards.